J.W. Cole Advisors’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$212K Buy
+857
New +$185K ﹤0.01% 1479
2026
Q1
Sell
-1,074
Closed -$222K 970
2025
Q4
$222K Sell
1,074
-57
-5% -$11.4K 0.01% 1251
2025
Q3
$203K Buy
+1,131
New +$193K ﹤0.01% 1434
2025
Q2
Sell
-1,193
Closed -$203K 1470
2025
Q1
$203K Buy
+1,193
New +$207K 0.01% 1153
2024
Q4
Sell
-1,183
Closed -$203K 973
2024
Q3
$203K Buy
+1,183
New +$196K 0.01% 903
2024
Q1
Sell
-1,310
Closed -$207K 892
2023
Q4
$207K Buy
+1,310
New +$188K 0.01% 754
2021
Q2
Sell
-1,541
Closed -$247K 746
2021
Q1
$247K Buy
+1,541
New +$264K 0.02% 574

Other funds holding FBT

J.W. Cole Advisors's FBT Position: Q2 2026 in Review

J.W. Cole Advisors opened a new position in First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q2 2026: 857 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #1479 among its holdings. This is a return to the name: J.W. Cole Advisors previously reported a position in FBT as recently as Q4 2025.

J.W. Cole Advisors first reported a position in FBT in Q1 2021 and has held it in 7 quarters since. The position peaked at $247K in Q1 2021. 339 funds tracked by Wall St. Rank hold FBT as of Q2 2026.

  • J.W. Cole Advisors held 857 shares of First Trust NYSE Arca Biotechnology Index Fund worth $212K as of Q2 2026.
  • First Trust NYSE Arca Biotechnology Index Fund was a new J.W. Cole Advisors position in Q2 2026.
  • First Trust NYSE Arca Biotechnology Index Fund made up ﹤0.01% of J.W. Cole Advisors's portfolio in Q2 2026, its #1479 holding.
  • J.W. Cole Advisors first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q1 2021 and has held it in 7 quarters since.
  • J.W. Cole Advisors's First Trust NYSE Arca Biotechnology Index Fund position peaked at $247K in Q1 2021.
  • 339 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q2 2026.

Based on J.W. Cole Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.